Transfer from: ammonia-based observation Time heroes. In the summer of 2021, in the face of the new coronary epidemic, MNF technology was well known for its excessive speed of research and development. However, even heroes are faced with the fallout of the epidemic. BioNTech and Moderna, the year that came from the emergence of a new MNF vaccine, are on the verge of income cutbacks. In 2022, BioNTech earned 1.7 billion euros from the new coroner vaccine, and in 2023, BioNTech’s performance is...